CAPR — Capricor Therapeutics, Inc.
Is CAPR overbought or oversold? Here is the current MarketMoodz read.
Capricor Therapeutics, Inc. (CAPR) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $8.41. The rating moved from Strong Oversold to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$8.41
- Last changeMoved from Strong Oversold to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Capricor Therapeutics is a small, development‑stage biopharma whose valuation is primarily driven by pipeline milestones and regulatory progress. Near‑term outlook hinges on upcoming clinical readouts, partnership prospects, and the company’s cash runway; absent positive data or a deal, financing needs and dilution are likely. Market liquidity and sector sentiment can introduce significant short‑term volatility. Investors should watch clinical timelines, cash burn, and any business development activity as primary catalysts and monitor payer/regulatory signals that could affect long‑term commercial prospects.
Key factors
- Development-stage biotech profile with pipeline assets that, if successful in clinical readouts, could drive material upside
- Limited or non‑material commercial revenue today; valuation heavily dependent on clinical and regulatory milestones
- Balance sheet and cash runway are likely finite; near‑term financing or partnerships may be required to fund ongoing programs
- Potential for strategic partnerships or acquisition interest from larger pharma players seeking specialty franchises
- Low trading liquidity and elevated share price volatility typical of small‑cap biotech stocks
- Regulatory environment and reimbursement dynamics for specialty therapies could materially affect commercial prospects
Risks
- Clinical trial failure or delayed readouts that materially reduce expected future value
- Need to raise capital via equity issuance, causing dilution to existing shareholders
- Regulatory setbacks, additional data requirements, or protracted approval timelines
- Competitive threats from better‑capitalized companies or alternative therapeutic approaches
- Reimbursement pressure or payer restrictions limiting pricing and market access
- Low liquidity and macro/sector rotation that can amplify downside in risk‑off conditions
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for CAPR — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.